How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,679 results for

aspirin and cancer prevention

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Rivaroxaban (Xarelto) - Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients

submission rivaroxaban (Xarelto ® ) is accepted for restricted use within NHSScotland. Indication under review: Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery disease at high risk of ischaemic events. SMC restriction: use in patients with stable coronary artery disease that does not require dual antiplatelet therapy. Addition of rivaroxaban to low-dose aspirin (acetylsalicylic (...) acid) reduced the incidence of a composite outcome that included stroke, cardiovascular death and myocardial infarction, mainly due to reductions in stroke and cardiovascular death. It also increased the incidence of major bleeding. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication Co-administered with acetylsalicylic acid (aspirin) for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery

2019 Scottish Medicines Consortium

2. Clopidogrel/Acetylsalicylic acid Teva

procedure under Article 3(2)(b) of Regulation (EC) No 726/2004 was based on demonstration of interest of patients at Community level. The applicant applied for the following indication : Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Fixed-dose combination medicinal product for continuation of therapy in: • Non ST segment elevation acute coronary syndrome (unstable angina (...) Teva is a fixed dose combination formulated as a substitution therapy used in prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). This is used for continuation of therapy in non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention and in ST segment elevation acute myocardial infarction

2014 European Medicines Agency - EPARs

3. Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer Full Text available with Trip Pro

Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer Aspirin's potential as a drug continues to be evaluated for the prevention of colorectal cancer (CRC). Although multiple targets for aspirin and its metabolite, salicylic acid, have been identified, no unifying mechanism has been proposed to clearly explain its chemopreventive effects. Our goal here was to investigate the ability of salicylic acid (...) . 2,3-DHBA and 2,6-DHBA did not inhibit CDK2 and 4; however, both inhibited CDK-6 activity. Interestingly, another derivative, 2,4,6-trihydroxybenzoic acid (2,4,6-THBA) was highly effective in inhibiting CDK1, 2, 4 and 6 activity. Molecular docking studies showed that these compounds potentially interact with CDK1. Immunoblotting experiments showed that aspirin acetylated CDK1, and pre-incubation with salicylic acid and its derivatives prevented aspirin-mediated CDK1 acetylation, which supported

2017 International journal of oncology

4. Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas Full Text available with Trip Pro

Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas Acetylsalicylic acid (ASA) is known as a cancer preventing agent, but there is no data available regarding the effect of ASA on pituitary cells. We investigated 66 nonfunctioning (NFPA) and growth hormone (GH)-producing adenomas and 15 normal pituitary samples. Functional assays (cell viability, proliferation, flow cytometry cell cycle analysis, caspase-3 activation and DNA degradation) were applied (...) phase of the cell cycle. Inhibition of survivin using an inhibitor or siRNA-mediated silencing reversed the ASA-induced growth inhibition partially. In addition, we also found survivin-independent effects of ASA on the cell cycle that were mediated through inhibition of cyclin A, cyclin dependent kinase 2 (CDK2) and phospho-CDK2. We also aimed to test the effect of acetylsalicylic acid in an animal model using RC-4 B/C cells, but in contrast to GH3 cells, RC-4 B/C cells failed to adhere and grow

2018 Oncotarget

5. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

the Committee, issued a positive opinion for granting a marketing authorisation to Tookad on 14 September 2017. 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy = 10 years and: - Clinical stage T1c or T2a, - Gleason Score = 6, based on high-resolution biopsy strategies, - PSA = 10 ng/mL, - 3 positive cancer cores (...) Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report

2017 European Medicines Agency - EPARs

6. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including (...) daily. • There is no recommendation for or against aspirin therapy in adults aged < 50 or = 60 years. • Exclude adults with increased risk of bleeding. This includes those with a history of gastrointestinal (GI) bleeding, GI ulcers, intracranial bleed, bleeding disorders, renal failure, severe liver disease, thrombocytopenia, or using NSAIDS daily, or other medicine to prevent blood clots. The recommendations above reflect a change from initiate to consider in adults aged 50-59 years with 10-year

2019 Kaiser Permanente National Guideline Program

7. Tumor-preventing activity of aspirin in multiple cancers based on bioinformatic analyses Full Text available with Trip Pro

Tumor-preventing activity of aspirin in multiple cancers based on bioinformatic analyses Acetylsalicylic acid was renamed aspirin in 1899, and it has been widely used for its multiple biological actions. Because of the diversity of the cellular processes and diseases that aspirin reportedly affects and benefits, uncertainty remains regarding its mechanism in different biological systems.The Drugbank and STITCH databases were used to find direct protein targets (DPTs) of aspirin. The Mentha (...) portal indicated that aspirin might have effects on multiple tumor suppressors, such as TP53, PTEN, and RB1 and that TP53 might play a central role in aspirin-associated genes.The results not only suggest that aspirin might have anti-tumor actions against multiple cancers but could also provide new directions for further research on aspirin using a bioinformatics analysis approach.

2018 PeerJ

8. Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic acid: a Potential Role in Cancer Prevention Full Text available with Trip Pro

Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic acid: a Potential Role in Cancer Prevention Data emerging from the past 10 years have consolidated the rationale for investigating the use of aspirin as a chemopreventive agent; however, the mechanisms leading to its anticancer effects are still being elucidated. We hypothesized that aspirin's chemopreventive actions may involve cell-cycle regulation through modulation of the levels or activity of cyclin A2/cyclin-dependent kinase-2 (...) (CDK2). In this study, HT-29 and other diverse panel of cancer cells were used to demonstrate that both aspirin and its primary metabolite, salicylic acid, decreased cyclin A2 (CCNA2) and CDK2 protein and mRNA levels. The downregulatory effect of either drugs on cyclin A2 levels was prevented by pretreatment with lactacystin, an inhibitor of proteasomes, suggesting the involvement of 26S proteasomes. In-vitro kinase assays showed that lysates from cells treated with salicylic acid had lower levels

2015 Molecular cancer research : MCR

9. Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. Full Text available with Trip Pro

Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. Emergence of drug-resistant cancer phenotypes is a challenge for anti-cancer therapy. Cancer stem cells are identified as one of the ways by which chemoresistance develops.We investigated the anti-inflammatory combinatorial treatment (DA) of doxorubicin and aspirin using a preclinical microfluidic model on cancer cell lines and patient-derived (...) circulating tumour cell clusters. The model had been previously demonstrated to predict patient overall prognosis.We demonstrated that low-dose aspirin with a sub-optimal dose of doxorubicin for 72 h could generate higher killing efficacy and enhanced apoptosis. Seven days of DA treatment significantly reduced the proportion of cancer stem cells and colony-forming ability. DA treatment delayed the inhibition of interleukin-6 secretion, which is mediated by both COX-dependent and independent pathways

2019 British Journal of Cancer

10. Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas. Full Text available with Trip Pro

Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas. Aspirin may reduce the risk of several types of cancer.To evaluate if folic acid is associated with risk of basal cell carcinoma (BCC).BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas (...) ·56); HR for 325 mg daily 1·33 (95% CI 0·80-2·20)]. BCC risk was higher with aspirin use in those without previous skin cancer but lower with aspirin use in those with previous skin cancer (Pinteraction = 0·02 for 81 mg aspirin daily; Pinteraction = 0·03 for 325 mg aspirin daily). Folic acid supplementation was unrelated to BCC incidence (HR 0·85; 95% CI 0·57-1·27).Neither aspirin nor folic acid treatment had a statistically significant effect on risk of BCC. Subgroup analysis suggested

2018 British Journal of Dermatology Controlled trial quality: predicted high

11. Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma

as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma Drug: Low dose of aspirin Detailed Description: Renal cell carcinoma (RCC) accounts for 2%~3% of all malignant tumors worldwide. In China, the incidence of renal cancer is increasing year by year. It is reported about one-third of patients were at late stage when diagnosed while about one-third of patients who received surgical treatment would eventually lead to recurrence or metastasis. The 5-years survival is only (...) about 50% in patients with locally advanced RCC, which lacks of effective adjuvant treatments, although the S-TRAC study showed improved Disease-free Survival (DFS) in high-risk renal cell carcinoma after nephrectomy. Aspirin, also called acetylsalicylic acid, belongs to non-steroidal anti-inflammatory drugs (NSAIDs). Its inhibitory effect on platelet aggregation makes it widely used in cardiovascular and cerebrovascular diseases. In addition, a number of epidemiology, basic and clinical researches

2018 Clinical Trials

12. Diagnosis and management of patients at risk of gastric adenocarcinoma Full Text available with Trip Pro

. pylori to reduce the incidence of gastric cancer in low-incidence areas such as the UK (evidence level: high quality; grade of recommendation: high; level of agreement: 100%). Several studies in rodents support the hypothesis that eradication of H. pylori infection prevents the subsequent development of gastric adenocarcinoma. However, the benefits were reduced in these animal models when infection was eradicated at later stages in the natural history of the disease. Multiple human cohort studies (...) efficacious treatments, including endoscopic resection,before cancer is established. The British Society of Gastroenterology (BSG) endoscopy committee agreed to create a guideline to provide statements and recommendations on the prevalence, risks, diagnosis, treatment, surveillance and screening of gastric premalignant and early gastric malignant lesions. The principal patient group are those found to have GA, GIM, gastric epithelial dysplasia or early gastric adenocarcinoma limited to the mucosal

2019 British Society of Gastroenterology

13. A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. Full Text available with Trip Pro

A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. To evaluate the relevance of adding acetylsalicylic acid (ASA) in primary prevention in subjects with type 2 diabetes mellitus.213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure (...) control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B). We assessed at baseline, at the end of Phase A, and at the end of Phase B the levels of some new emerging biomarkers of cardiovascular risk including: high sensitivity C-reactive protein (Hs-CRP), adiponectin (ADN), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), myeloperoxidase (MPO), soluble CD40 ligand (sCDL40

2015 Cardiovascular diabetology Controlled trial quality: uncertain

14. The apoptotic inducible effects of salicylic acid on hepatoma cell line: relationship with nitric oxide signaling Full Text available with Trip Pro

The apoptotic inducible effects of salicylic acid on hepatoma cell line: relationship with nitric oxide signaling Clinical and experimental data suggest that salicylic acid (SA) is tumor preventive and NO has a multitude of effects on tumor biology. Therefore, firstly, the aim of our study is to explore the important role of SA in apoptotic induction of liver cancer cells. Secondly, we investigate whether SA mediates the anti-tumor effects by NO signaling pathway. The liver cancer cell line (...) activities in above process. Importantly, SA up-regulated a series of apoptosis-related gene expression and reduced the mRNA level of HMGB1. Meanwhile, we also found that NOS inhibitor L-NAME and NO scavenger cPTIO attenuated the above SA-induced effects. Thus, we provided the evidence that SA exerted anti-tumor effects in liver cancer cell in part mediated by the NO pathway.

2017 Journal of cell communication and signaling

15. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases Full Text available with Trip Pro

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous thrombosis (935/565), pooling three independent cohorts previously reported. Long-term treatment with antiplatelet drugs or vitamin K-antagonists (VKA) was given to 1391 (92.7%) patients; 975 (65%) patients received (...) by VKA (HR 0.60, 95% CI 0.37-0.95), while HU prevented late but not early recurrences after venous thrombosis at common sites. Of note, we failed to demonstrate a positive effect of HU in the prevention of recurrent splanchnic vein thrombosis. In conclusion, in MPN patients, HU plays a role in the prevention of arterial thrombosis, together with aspirin and VKA, whereas its action in the prevention of recurrent venous thrombosis is uncertain. Such findings call for future studies to optimize

2018 Blood cancer journal

16. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 with the exception that the SUV max is used in the United States as the quantitative measurement

extremi- ties.Inpatientswithtumourswithahighriskofhead and brain metastasis but not metastasis in the lower extremities (e.g. lung cancer), it may be appropriate to performanextendedtorsoFDGPET/CTscanincluding thebraininthesamescan[53]. Limited-view tumour imaging can be considered for follow-up examinations if the disease is restricted to a defined region (e.g. solitary pulmonary nodule, suspicion of lung cancer, examination of hilar lymph nodes, head and neck tu- mours,assessmentoftherapyresponse (...) metastases. & Increased FDG uptake is observed in many neoplastic lesions, granulation tissue (e.g. wound healing), infections andotherinflammatoryprocesses.Adetaileddescriptionof pitfallsandsituationsthatcanleadtofalse-positive(benign processes that can show FDG uptake) or false-negative FDG PET/CTinterpretation has been published [67]. Eur JNuclMedMol Imaging(2015) 42:328–354 343& Patterns of FDG uptake, established CT morphological criteria and correlation with patient history, physical ex- amination

2018 Society of Nuclear Medicine and Molecular Imaging

17. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force

Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 133. 2015 Authors' objectives We conducted

2015 Health Technology Assessment (HTA) Database.

18. Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action

interval of ASA administration for the anticancer effect detected in cardiovascular trials. These patients will be stratified into individuals with adenomas/carcinomas (20 to 30%) and patients without clinically detected adenomas/carcinomas (about 70 to 80%). Condition or disease Intervention/treatment Phase Colorectal Cancer Drug: Acetylsalicylic acid Procedure: Screening colonoscopy Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated (...) Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2014 Clinical Trials

19. Salicylic Acid Plaster

Salicylic Acid Plaster Salicylic Acid Plaster Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Salicylic Acid Plaster Salicylic Acid (...) Plaster Aka: Salicylic Acid Plaster , Mediplast From Related Chapters II. Indication III. Preparation Salicylic Acid Plaster 40% (Mediplast) IV. Technique Precede application with warm water soaks 10-15 min Cut plaster to fit exactly over wart Consider using hole punch Secure with adhesive tape at bedtime Remove in morning Alternatively leave in place for 24 to 48 hours Carefully scrape away macerated wart tissue Consider use of pumice stone V. Efficacy Older method, but effective Expect slow

2018 FP Notebook

20. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults aged 50 to 59 years with a ≥10% 10-year CVD risk The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (...) cancer incidence and mortality outcomes would be helpful. Additional research is needed to better estimate the harms of aspirin-induced GI bleeding. Development of an externally validated risk assessment tool for bleeding that could be used at the point of care would be helpful. A tool that considers both CVD risk and GI bleeding risk would be useful to clinicians and patients when deciding whether to start or continue aspirin use for primary prevention. Burden of Disease Cardiovascular disease

2016 U.S. Preventive Services Task Force

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>